H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma Ltd (URGN) today and set a price target of $75. The company’s shares closed yesterday at $37.75, close to its 52-week low of $34.61.
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.1% and a 34.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Urogen Pharma Ltd with a $65 average price target.
See today’s analyst top recommended stocks >>
Based on Urogen Pharma Ltd’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $23.72 million. In comparison, last year the company had a GAAP net loss of $13.38 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology.
